Arcturus teams up with Thermo Fisher on mRNA therapy
Arcturus Therapeutics Holdings (NASDAQ:ARCT) announced a strategic collaboration with Thermo Fisher Scientific (NYSE:TMO) to support Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis.








_1432286_640x360_2505407555986-640x360.webp&w=3840&q=75)

_1432277_640x360_2505409603882-640x360.webp&w=3840&q=75)
